Search Results

The Trinity Biotech Captia™ Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the qualitative detection of Measles IgM antibodies in human serum of patients suspected of measles (rubeola) infection. This assay is intended for use as an aid in the diagnosis of a current or recent measles (rubeola) infection in conjunction with other clinical information and laboratory findings.

Performance characteristics have not been evaluated in immunocompromised or immunosuppressed individuals. This test is not intended for use in neonatal screening or for use at a point of care. This test is not intended for use in screening blood and plasma donors.

The Trinity Biotech Captia™ Measles IgM test is an Enzyme-Linked Immunosorbent Assays (ELISA). When measles antigen (Edmonston strain) is bound to the solid phase and brought into contact with a patient's serum, antigen specific antibody, if present, will bind to the antigen on the solid phase forming antibody complexes. Excess antibody is removed by washing. This is followed by the addition of goat anti-human IgM globulin conjugated with horseradish peroxidase which will bind to the antibody-antigen complexes. The excess conjugate is removed by washing, followed by the addition of Chromogen/Substrate tetramethylbenzidine (TMB). If specific antibody to the antigen is present in the patient's serum, a blue color develops. When the enzymatic reaction is stopped with 1N H2SO4. The contents of the wells turn yellow. The color, which is indicative of the concentration of antibody in the serum, can be read on a suitable spectrophotometer or ELISA microwell plate reader.

Here's an analysis of the acceptance criteria and the studies performed for the Trinity Biotech Captia™ Measles IgM ELISA Test Kit, presented in the requested format:

Acceptance Criteria and Device Performance for Trinity Biotech Captia™ Measles IgM ELISA

The provided document describes the performance characteristics and clinical studies of the Trinity Biotech Captia™ Measles IgM ELISA. The acceptance criteria are not explicitly stated as pass/fail thresholds in a dedicated table, but are inferred from the reported performance characteristics.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Sizes and Data Provenance

• Test Set (Clinical Studies 1 & 2): 188 samples from suspected measles infection cases.
  • Data Provenance: Retrospective, collected from individuals in whom a measles IgM test was ordered by the Texas Department of Health, Austin, Texas (66 samples) and the State Laboratory of Public Health in Raleigh, North Carolina (122 samples), USA.
• Test Set (Clinical Study 3): 8 samples.
  • Data Provenance: Retrospective, collected from submissions to the Kansas Department of Health and Environment Laboratory (KDHE), Topeka, Kansas, USA.
• Test Set (Specificity in a Normal Population): 200 random serum samples.
  • Data Provenance: Not explicitly stated, but implied to be from a general population (individuals between ages 18-65 with no known clinically apparent Measles infection). Location not specified.
• Test Set (Cross-Reactivity): 47 samples.
  • Data Provenance: Confirmed positive for other IgM antibodies (CMV, HSV1, HSV2, Rubella, VZV, Mumps, Parvo-B19) by Trinity Biotech Captia™ test kits. Location not specified.
• Test Set (Precision/Reproducibility): 6 blinded panel members (4 low-to-moderate positive, 2 negative).
  • Data Provenance: Not specified, likely internal or commercially sourced panels.

3. Number of Experts and Qualifications for Ground Truth

• The document does not specify the number of experts used to establish the ground truth for the test sets in the clinical studies.
• The ground truth in Clinical Studies 1 & 2 was established using a "comparator testing algorithm" which consisted of "the results of other laboratory confirmation methods including comparator Measles IgM ELISA test kit, a comparator Measles IgM IFA test kit, Complement Fixation (CF), Hemagglutionation Inhibition (HI) and the Trinity Biotech Captia™ Measles ELISA IgG test kit." This implies multiple laboratory results were used to form a consensus or a defined algorithm, rather than individual expert adjudication of each case.
• Similarly, in Clinical Study 3, the "comparator algorithm included RNA polymerase chain reaction (PCR) on urine, nasopharyngeal swab (NPS) and/or throat swab (TS) samples."

4. Adjudication Method for the Test Set

• For Clinical Studies 1 & 2, the ground truth was established by a "comparator algorithm" based on multiple laboratory confirmation methods (e.g., other ELISAs, IFA, CF, HI). The specific adjudication rule (e.g., 2 out of 3, 3 out of 4) is not explicitly detailed, but it generally implies a form of consensus derived from multiple test results rather than human expert adjudication.
• For Clinical Study 3, the ground truth was established by a "comparator algorithm" based on PCR results from various sample types. Again, the specific adjudication rules for discrepant PCR results (e.g., "NPS negative at two sites, urine positive at one site and urine indeterminate at one site") are not explicitly detailed for how the final "positive," "indeterminate," or "negative" comparator algorithm result was reached.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• No, an MRMC comparative effectiveness study was not performed. This device is an Enzyme-Linked Immunosorbent Assay (ELISA), which is an automated or semi-automated laboratory test. It does not involve human readers interpreting images or data where AI assistance would be applicable in the traditional sense of an MRMC study for imaging diagnostics. The "readers" are the laboratory technicians operating the ELISA equipment.

6. Standalone Performance Study

• Yes, standalone performance was done for the device. All reported performance metrics (analytical performance, seroconversion, cross-reactivity, clinical agreement with comparator algorithms) represent the performance of the Captia™ Measles IgM ELISA as an algorithm/device only, without human "in-the-loop" assistance for interpreting the result of the ELISA itself. While humans perform the test and interpret the final ISR value against predefined cut-offs, the "algorithm" is determining the ISR.

7. Type of Ground Truth Used

• The ground truth used was a combination of other laboratory confirmation methods and algorithms.
  • For Clinical Studies 1 & 2: "comparator testing algorithm used at each institution to determine the presence of current or recent measles infection" which included "comparator Measles IgM ELISA test kit, a comparator Measles IgM IFA test kit, Complement Fixation (CF), Hemagglutionation Inhibition (HI) and the Trinity Biotech Captia™ Measles ELISA IgG test kit." This represents a form of expert-defined algorithm/consensus from multiple laboratory tests.
  • For Clinical Study 3: "comparator algorithm included RNA polymerase chain reaction (PCR) on urine, nasopharyngeal swab (NPS) and/or throat swab (TS) samples." This is essentially molecular pathology/laboratory results.
  • For Cross-Reactivity: Confirmed positive status based on other specific IgM ELISA tests.
  • For Seroconversion: A commercially available seroconversion panel.

8. Sample Size for the Training Set

• The document does not explicitly state a separate "training set" in the context of machine learning model development. This is an ELISA kit, not typically a machine learning algorithm that requires a distinct training phase in the same way. The development and optimization of the assay (e.g., antigen titration, calibrator development, component formulation) would be part of an iterative development process that could be considered analogous to "training," but not in the sense of a labeled dataset for an AI model.
• The cut-off determination study involved 228 Measles IgM negative sera, which were used to establish the positive threshold (mean + 4SD). This could be considered a form of "training" or "calibration" data for the assay's interpretive criteria.

9. How the Ground Truth for the Training Set Was Established

• As noted above, there isn't a traditional "training set" for a machine learning algorithm.
• For the cut-off determination, the 228 Measles IgM negative sera were explicitly described as "Measles IgM negative sera" and were used to calculate statistical parameters (mean and standard deviation of optical density readings) to define the initial positive threshold. Four samples were disqualified because they were in the equivocal range on Trinity IgM ELISA or indeterminate on a comparator Measles IFA test kit (due to non-specific staining). This implies an initial screening or pre-classification of these samples as "negative" before their use in cut-off calculation. The final cut-off was derived using these empirical observations.

Ask a specific question about this device

The Trinity Biotech Captia™ Herpes Simplex Virus (HSV) 1 Type Specific IgG kit is an Enzyme-linked Immunosorbent Assay (ELISA) intended for qualitatively detecting the presence or absence of human IgG class antibodies to HSV-1 in human serum. In conjunction with the Trinity Biotech Captia™ Herpes Simplex Virus (HSV) 2 Type Specific IgG kit, the test is indicated for testing sexually active adults or expectant mothers for aiding in the presumptive diagnosis of HSV infection. Due to the implications of positive results, it is recommended they be confirmed in a low prevalence population with Western blot. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, for testing of immunocompromised patients, or for use with automated equipment. The user is responsible for establishing assay performanace in these populations and with automated equipment

The Captia™ HSV 1 IgG Type Specific kit is an Enzyme-Linked Immunosorbent Assav (ELISA) for the qualitative determination of IgG antibodies in human serum to Herpes simplex Type 1 antigen. The Captia™ HSV 1 IgG Type Specific assay may be used as an aid in the diagnoses of Herpes infection.

For In Vitro Diagnostic Use Only.

The Captia™ HSV 1 IgG Type Specific test is an Enzyme-Linked Immunosorbent assay to detect IgG antibodies to Herpes simplex 1 antigen. Purified recombinant HSV gG1 antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. If antibody is present, it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.

Here's a breakdown of the acceptance criteria and study information for the Captia™ HSV 1 IgG Type Specific ELISA Test Kit, based on the provided text:

Acceptance Criteria and Reported Device Performance

The acceptance criteria are implicitly defined by the performance characteristics presented in the study. The device is deemed acceptable if its agreement with the predicate device (Western Blot or other ELISA) falls within certain confidence intervals, demonstrated across various patient populations.

Study Details

1. Sample sizes used for the test set and the data provenance:

   • Expectant Mothers: n = 210 sera. Data provenance: Consented, coded, unselected, banked, and masked sera. Country of Origin: Not specified beyond "Pacific Northwest university" which references the Western Blot. Retrospective (banked sera).
   • Sexually Active Adults: n = 198 sera. Data provenance: Consented, unselected, and masked sera. Country of Origin: Not specified beyond "Pacific Northwest university". Retrospective (masked sera implies pre-collected).
   • Low Prevalence Population: n = 184 sera. Data provenance: Unselected, banked, and masked sera. Country of Origin: Not specified beyond "Pacific Northwest university". Retrospective (banked sera).
   • Culture Positives: n = 53 sera. Data provenance: Unselected, retrospective, and masked sera from patients at least six weeks but not more than one year post clinical presentation and culture. Country of Origin: Not specified beyond "Pacific Northwest university". Retrospective.
   • Alternate HSV 1 Type Specific IgG ELISA Comparison: n = 200 specimens. Data provenance: Prospective, unselected, sequentially submitted specimens. Country of Origin: Not specified beyond "Pacific Northwest University".
   • Type Specificity with HSV 2 Western Blot Positives: n = 56 sera. Data provenance: Samples from the "above described populations" (expectant mothers, sexually active adults, low prevalence persons, and HSV 2 culture positives) that were HSV 2 Western Blot positive and HSV 1 Western Blot negative. Country of Origin: Not specified beyond "Pacific Northwest University". Retrospective.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
   The document does not explicitly state the number or qualifications of experts used to establish the ground truth. The ground truth (reference method) was established by an "HSV 1 Western Blot (WB) from a Pacific Northwest university" or "culture" for some cases. While Western Blot interpretation requires expertise, no details about the experts are provided.

3. Adjudication method for the test set:
   The document does not mention an adjudication method for the test set. Results from the Trinity ELISA were compared directly against the Western Blot or culture reference method. For the expectant mothers and low prevalence population studies, "equivocal" results from the Trinity ELISA were excluded from the percentage agreement calculations but reported in the raw counts.

4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
   No, a multi-reader, multi-case (MRMC) comparative effectiveness study was not done. This device is an in-vitro diagnostic ELISA kit, not an AI-assisted diagnostic tool that would involve human readers interpreting results with or without AI. The evaluation is solely on the performance of the assay itself compared to a reference method.

5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
   Yes, the studies presented are all standalone performance evaluations of the Captia™ HSV 1 IgG Type Specific ELISA kit. The performance metrics (e.g., % agreement positive, % agreement negative) are direct comparisons between the ELISA results and the reference method (Western Blot or culture) without human interpretation being factored in beyond the initial reading of the ELISA and the reference method itself.

6. The type of ground truth used:
   The primary type of ground truth used was:

   • Expert Consensus / Established Reference Method: Western Blot (HSV 1 Western Blot, HSV 2 Western Blot). The Western Blot is considered a gold standard for type-specific HSV serology.
   • Pathology / Outcomes Data: Culture (for the "Culture Positives" study), indicating active infection.

7. The sample size for the training set:
   The document does not provide information on a training set. The presented studies are performance evaluations of the final device, implying that any training and development would have occurred prior to these validation studies. Therefore, the sample sizes mentioned are for the test sets.

8. How the ground truth for the training set was established:
   Since no training set details are provided, the method for establishing its ground truth is also not mentioned.

Ask a specific question about this device

The Trinity Biotech Captia™ Herpes Simplex Virus (HSV) 2 Type Specific IgG kit is an Enzyme-linked Immunosorbent Assay (ELISA) intended for qualitatively detecting the presence or absence of human IgG class antibodies to HSV-2 in human serum. In conjunction with the Trinity Biotech Captia™ Herpes Simplex Virus (HSV) I Type Specific IgG kit, the test is indicated for testing sexually active adults or expectant mothers for aiding in the presumptive diagnosis of HSV infection. Due to the implications of positive results, it is recommended they be confirmed in a low prevalence population with Western blot. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, for testing of immunocompromised patients, or for use with automated equipment. The user is responsible for establishing assay performance in these populations and with automated equipment.

The CaptiaTM HSV 2 IgG Type Specific kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative determination of IgG antibodies in human serum to Herpes simplex Type 2 antigen. The Captia™ HSV 2 IgG Type Specific assay may be used as an aid in the diagnoses of Herpes infection. Purified recombinant HSV gG2 antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. If antibody is present, it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.

The provided document details the performance characteristics of the Captia™ HSV 2 IgG Type Specific ELISA Test Kit. Here's a breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined acceptance criteria (e.g., "The device must achieve X% sensitivity and Y% specificity"). Instead, it presents the performance of the device against a predicate device (Western Blot) and an alternate ELISA. The reported performance is summarized below from different study populations. The predicate device used for comparison is the Western Blot (WB) from a Pacific Northwest university.

2. Sample Size Used for the Test Set and Data Provenance

The document describes several distinct test sets:

• Expectant Mothers:
  • Sample Size: n = 210
  • Data Provenance: Consented, coded, unselected, banked, and masked sera. The reference method (Western Blot) was from a Pacific Northwest university. This suggests retrospective data.
• Sexually Active Adults:
  • Sample Size: n = 198
  • Data Provenance: Consented, unselected, and masked sera. The reference method (Western Blot) was from a Pacific Northwest university. This suggests retrospective data.
• Low Prevalence Population:
  • Sample Size: n = 184
  • Data Provenance: Unselected, banked, and masked sera. The reference method (Western Blot) was from a Pacific Northwest university. This suggests retrospective data.
• Culture Positives:
  • Sample Size: n = 56
  • Data Provenance: Unselected, retrospective, and masked sera from patients at least six weeks but not more than one year post clinical presentation and culture HSV 2 positive. Reference methods (culture and Western Blot) were from a Pacific Northwest university.
• Prospectively Collected, Sequential Sera (vs. Alternate ELISA):
  • Sample Size: n = 200
  • Data Provenance: Prospective, unselected, sequentially submitted specimens. Collected by an outside investigator at a Pacific Northwest University.
• Type Specificity with HSV 1 Western Blot Positives:
  • Sample Size: n = 292
  • Data Provenance: HSV 1 Western Blot positive and HSV 2 Western Blot negative sera from the above described populations (expectant mothers, sexually active adults, low prevalence persons, and HSV 1 culture positives). Collected by an outside investigator at a Pacific Northwest University. This is a retrospective analysis of previously collected samples.

In general, the data seems to be from the United States (Pacific Northwest university) and is predominantly retrospective (banked, unselected, masked, retrospective sera), with one prospective study for comparison against an alternate ELISA.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not explicitly mention "experts" in the context of establishing ground truth. The ground truth for comparative studies is established by reference methods, primarily:

• Western Blot (WB): From a "Pacific Northwest university." No specific detail on the qualifications of the individuals performing or interpreting the Western Blot.
• Culture (for Culture Positives set): Implies standard laboratory procedure for viral culture, not explicitly associated with "experts" in this context.

Therefore, the specific number and qualifications of experts beyond the unspecified standard practices of a university lab for performing Western Blots and cultures are not detailed in the provided information.

4. Adjudication Method for the Test Set

The document does not describe an adjudication method (e.g., 2+1, 3+1). The comparisons are directly between the Captia™ ELISA and the reference method results. There's no mention of a process where multiple readers or experts review discordant results to reach a consensus.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This device is an in-vitro diagnostic (ELISA test kit) and does not involve human readers interpreting images or results, nor does it incorporate AI. Its performance is measured directly against laboratory reference standards.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

Yes, the studies presented describe the standalone performance of the Captia™ HSV 2 IgG Type Specific ELISA Test Kit. This is an enzymatic immunoassay (ELISA) performed in a laboratory setting, and its efficacy is measured by comparing its outputs directly against established reference methods (Western Blot, culture, or another ELISA). There is no "human-in-the-loop" component in the performance evaluation described, beyond the technical execution of the tests themselves.

7. The type of ground truth used

The primary type of ground truth used across the various studies is:

• Reference Standard (Western Blot): The Western Blot (WB) method from a Pacific Northwest university served as the gold standard for serological detection of HSV 2 IgG antibodies in most studies.
• Culture: For the "Culture Positives" group, the ground truth for actual infection was established by HSV 2 culture positivity.
• Alternate ELISA: In one study, another commercially available HSV 2 type-specific IgG ELISA was used as a comparative reference.

8. The sample size for the training set

The document provides performance data based on comparative studies with clinical samples. It does not mention a "training set" in the context of machine learning or algorithm development. This is a traditional IVD device, not an AI-driven algorithm. The performance evaluation focuses on the device's accuracy against established reference methods using specific test populations.

9. How the ground truth for the training set was established

As there is no explicit "training set" described for the development of a machine learning algorithm, this question is not applicable. The device's underlying mechanism is a biochemical ELISA, not an algorithm that learns from data. Its "ground truth" for development would relate to the antigen/antibody interactions it's designed to detect.

Ask a specific question about this device

The Trinity Biotech Captia™ Legionella pneumophila IgG/IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative detection of total antibodies (IgG and IgM) to serogroups 1-6 in serum from patients with clinical suspicion of Legionella Disease. The assay is not intended to differentiate between the serotypes of Legionella pneumophila.

The Legionella pneumophila IgG/IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative detection of total antibodies (IgG and IgM) to Legionella pneumophila serogroups 1-6 in serum from patients with clinical suspicion of Legionella Disease.

The Legionella pneumophila IgG/IgM ELISA test is an enzyme linked immunosorbent assay to detect IgG/IgM antibodies to legionella. Purified Legionella pneumophila antigen (serogroups 1, 2, 3, 4, 5, 6) is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG/IgM is added to each well. If antibody is present, it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.

Here's a breakdown of the acceptance criteria and study details for the Trinity Biotech Legionella pneumophila IgG/IgM ELISA Test Kit, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document doesn't explicitly state pre-defined acceptance criteria in terms of numerical thresholds for sensitivity, specificity, or agreement. Instead, it presents the results of a comparative study against a predicate device (Legionella IFA) and implicitly suggests that these results demonstrate substantial equivalence. The precision study evaluates consistency rather than diagnostic accuracy.

Ask a specific question about this device

The Trinity Biotech Captia™ Mycoplasma IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for semi-quantitative or qualitative determination of IgG antibodies in human serum to Mycoplasma pneumoniae for the determination of immunological experience. The Mycoplasma IgG ELISA kit may be used to evaluate paired sera for seroconversions and the presence of a significant increase in specific IgG as and aid in the diagnosis of Mycoplasma pneumoniae infection in the adult population.

The Mycoplasma IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for semi-quantitative or qualitative determination of IgG antibodies in human serum to Mycoplasma pneumoniae for the determination of immunological experience. The Mycoplasma IgG ELISA kit may be used to evaluate paired sera for the presence of seroconversions and a significant increase in specific IgG as an aid in the diagnosis of Mycoplasma pneumoniae infection in the adult population. For In Vitro Diagnostic Use Only.

The Mycoplasma IgG ELISA test is an enzyme linked immunosorbent assay to detect IgG antibodies to Mycoplasma pneumoniae. Purified Mycoplasma pneumoniae antigen is attached to a solid phase microtiter well. Diluted test sera are added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period the reaction is stopped and the color intensity is measured photometrically, producing and indirect measurement of specific antibody in the patient specimen.

Here's an analysis of the provided text, focusing on the acceptance criteria and the study proving the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

Note on Acceptance Criteria: The document primarily presents performance characteristics and compares them to a predicate device or implied standards (e.g., "With appropriate technique the user should obtain precision of

Ask a specific question about this device

The Trinity Biotech Captia™ H. pylori IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative determination of IgG antibodies in human serum to Helicobacter pylori, as an aid in the diagnosis of H. pylori infection in adult patients with clinical signs and symptoms of gastrointestinal disease, and is not intended for use in asymptomatic patients.

The H. pylori IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative determination of IgG antibodies in human serum to antigen. The Trinity Pylori IgG ELISA assay may be used as an aid in the diagnosis of Helicobacter pylori infection in persons with gastrointestinal symptoms. For In Vitro Diagnostic Use Only.

The H. pylori IgG ELISA test is an enzyme linked immunosorbent assay to detect IgG antibodies to Helicobacter pylori. Purified Helicobacter pylori antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. If antibody is present it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.

The provided document is a 510(k) premarket notification for the Trinity Biotech H. pylori IgG ELISA test kit. It describes the device, its predicate device, and performance characteristics, but does not explicitly state formal acceptance criteria. However, we can infer the performance targets based on the comparison to the predicate device and the presented results.

Here is an analysis based on the provided information:

Acceptance Criteria and Reported Device Performance

Note on Inferred Acceptance Criteria: The document primarily demonstrates substantial equivalence to "biopsy" (culture or stain) and to a predicate device (Pylori Stat). Therefore, the "acceptance criteria" are implicitly met if the performance characteristics are deemed substantially equivalent to these established methods. The exact numerical thresholds for acceptance are not explicitly listed, but the device's performance falling within the confidence intervals and showing high agreement suggests it met the unstated bar for equivalence.

Study Details

1. Sample size used for the test set and the data provenance:

   • Pylori Stat (Predicate Device) Evaluation: 386 serum samples.
     • Data Provenance: From five geographically different areas.
     • Retrospective/Prospective: Not explicitly stated, but samples were "having biopsy with stain or culture results," suggesting a retrospective collection of samples with known outcomes.
   • Trinity Biotech H. pylori IgG ELISA Evaluation: 371 serum samples.
     • Data Provenance: From five geographically different areas.
     • Retrospective/Prospective: Not explicitly stated, but samples were "having biopsy with stain or culture results," suggesting a retrospective collection of samples with known outcomes.
   • Precision Test: Six different serum samples, each tested ten times over three days (total of 180 individual tests for CV calculation).
   • Cross-Reactivity Test: Paired sera from 5 C. jejuni infections, 4 single sera from C. fetus infections, and 10 sera positive for Borrelia burgdorferi.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • The ground truth for the test set was established by "biopsy with stain or culture results for H. pylori."
   • The document does not specify the number of experts, their qualifications (e.g., pathologist, microbiologist), or the process involved in interpreting these biopsy/culture results.

3. Adjudication method for the test set:

   • The document explicitly states that "Equivocals were not included in the above calculations" for sensitivity, specificity, and agreement calculations. This implies that any samples yielding "equivocal" results from the ELISA tests were excluded from the primary performance metrics. There is no mention of an adjudication process to re-classify these equivocal results or conflicting ground truth interpretations.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No, an MRMC comparative effectiveness study was not done. This report describes the performance of an in vitro diagnostic (IVD) ELISA kit, which is a laboratory test, not an AI-assisted diagnostic tool for human readers. Therefore, there is no "human readers improve with AI vs without AI assistance" component.

5. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

   • Yes, a standalone performance study was done. The entire evaluation of the Trinity Biotech H. pylori IgG ELISA against biopsy and against the predicate device is a standalone performance assessment of the diagnostic kit itself, without human interpretation influencing the test result once the serum is processed by the ELISA method. The "interpretation" of the ELISA results (positive, negative, equivocal) is inherent to the kit's design and predetermined cut-offs.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

   • The primary ground truth used was pathology in the form of "biopsy with stain or culture results for H. pylori."
   • For cross-reactivity, ground truth for C. jejuni and C. fetus was established by "culture" (fecal culture on Campylobacter-specific media for C. jejuni, blood culture for C. fetus). For Borrelia burgdorferi, it was "positive for antibodies by ELISA and Western Blot."

7. The sample size for the training set:

   • The document does not mention a training set in the context of an algorithm or machine learning model. This is an ELISA kit, which is a biochemical assay with established protocols and reagents. Its "training" is more akin to assay development and optimization, rather than a data-driven machine learning training phase. The described studies are performance validation studies.

8. How the ground truth for the training set was established:

   • As there is no explicit training set in the context of an algorithm, this question is not applicable. The development and optimization of such a kit would rely on known positive and negative samples, but these are part of the assay development, not a "training set" with ground truth in the current sense of diagnostic AI.

Ask a specific question about this device

The Trinity Biotech Captia™ Borrelia burgdorferi IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative presumptive detection of IgM antibodies to Borrelia burgdorferi in human serum. This ELISA should be used for patients with signs and symptoms that are consistent with Lyme disease. Equivocal or positive results must be supplemented by testing with a standardized Western blot procedure. Positive supplemental results are supportive evidence of exposure to B. burgdorferi and can be used to support a clinical diagnosis of Lyme disease.

The Borrelia burgdorferi IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative presumptive detection of IgM antibodies to Borrelia burgdorferi in human serum. This ELISA should only be used for patients with signs and symptoms that are consistent with Lyme disease. Equivocal or positive results must be supplemented by testing with a standardized Western blot procedure. Positive supplemental results are supportive evidence of exposure to B. burgendorferi and can be used to support a clinical diagnosis of Lyme disease.

The Borrelia burgdorferi IgM ELISA test is an enzyme linked immunosorbent assay to detect IgM antibodies to Borrelia burgdorferi. Purified Borrelia burgdorferi antigen is attached to a solid phase microtiter well. Pretreated test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgM is added to each well. If antibody is present it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.

The provided document describes the Trinity Biotech Borrelia burgdorferi IgM ELISA Test Kit, an immunoassay for the qualitative detection of IgM antibodies to Borrelia burgdorferi (the causative agent of Lyme disease) in human serum.

Here's an analysis of the acceptance criteria and the studies performed:

1. Table of Acceptance Criteria and Reported Device Performance:

The document does not explicitly state pre-defined acceptance criteria (e.g., "The device must achieve X sensitivity and Y specificity"). Instead, it presents performance characteristics from comparative studies against clinical diagnosis and a predicate device (BioWhittaker's Lyme M STAT test) combined with Western Blot confirmation.

Implicit Acceptance Criteria (inferred from context and comparison to predicate):

*   **Data Provenance:** From the CDC (Centers for Disease Control and Prevention). This suggests the data is likely retrospective, as it's a "panel obtained from the CDC." The country of origin is the USA.

• Study 2 (Comparative Effectiveness with Predicate):
  • Sample Size: 176 sera.
  • Data Provenance: From patients submitted to a large clinical lab for B. burgdorferi antibody testing. This suggests the data is retrospective, collected from existing patient samples. The country of origin is not explicitly stated but implied to be the USA given the context of the submission.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:

• Study 1 (CDC Lyme Disease Serum Panel): The ground truth is described as "clinical diagnosis" and the panel samples were "masked, characterized serum panel." While the document doesn't specify the exact number or qualifications of experts involved in establishing the clinical diagnosis for this CDC panel, CDC panels are typically established by expert consensus of clinicians and specialists in infectious diseases, based on a comprehensive review of clinical, epidemiological, and laboratory data.
• Study 2 (Comparative Effectiveness with Predicate): The ground truth for this study was established by Mardx Diagnostics Western Blot for both IgG and IgM for any serum found positive or equivocal by either ELISA. This is a laboratory-based gold standard, not directly established by medical experts in this context.

4. Adjudication Method for the Test Set:

• Study 1 (CDC Lyme Disease Serum Panel): "Because the equivocals would have been tested by immunoblotting in a 2-step test system, they were considered 1-step positive for purposes of calculating % agreement." This indicates a specific rule for handling equivocal results in the calculation, rather than a multi-reader/multi-expert adjudication.
• Study 2 (Comparative Effectiveness with Predicate): Equivocal or positive ELISA results were further tested by Western Blot. There's no mention of adjudication between multiple readers for the Western Blot results; the Western Blot itself served as the confirmatory method.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was Done:

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not explicitly stated or described. The studies focus on device performance (ELISA) against a clinical diagnosis panel or a predicate device and Western Blot, not on the impact of the device on human reader performance.

6. If a Standalone Study (Algorithm Only Without Human-in-the-Loop Performance) was Done:

Yes, the studies presented are primarily standalone performance evaluations of the ELISA kit. The ELISA kit generates a quantitative result which is then interpreted qualitatively (positive, equivocal, negative). This process does not involve human interpretation within a diagnostic workflow that the device is assisting, but rather the device itself provides the result.

7. The Type of Ground Truth Used:

• Study 1: Clinical Diagnosis (from the CDC panel).
• Study 2: Western Blot (laboratory-based gold standard).

8. The Sample Size for the Training Set:

The document does not provide information regarding a "training set" or its size. This is typical for traditional in vitro diagnostic (IVD) device submissions (like an ELISA kit), where the device development process might involve internal optimization and validation, but not a formally separate "training set" and "test set" in the same way as machine learning or AI algorithm development. The studies presented are "test set" or "validation set" studies for the final device.

9. How the Ground Truth for the Training Set Was Established:

As no training set is described, this question is not applicable to the provided information.

Ask a specific question about this device

The Trinity Biotech Captia™ Chlamydia IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for qualitative detection of IgG antibodies in human serum to Chlamydia for the determination of immunological experience.

The Chlamydia IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for qualitative detection of IgG antibodies inhuman serum to Chlamydia for the determination of immunological experience.

The Chlamydia IgG ELISA test is an enzyme linked immunosorbent assay to detect IgG antibodies to Chlamydia. Purified Chlamydia antigen (strain LGV II) is attached to a solid phase microtiter well. Diluted test sera are added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. If antibody is preset it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.

Here's an analysis of the provided text, focusing on the acceptance criteria and the study proving the device meets them:

Acceptance Criteria and Device Performance for Trinity Biotech Chlamydia IgG ELISA Test Kit

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are implicitly defined by the reported performance relative to a predicate device and established precision standards.

• % Agreement Negative: High agreement with predicate IFA kit.
• % Agreement: High overall agreement with predicate IFA kit. | % Agreement Positive: 92.1% (95% CI: 86.3% - 97.8%)
  % Agreement Negative: 98.0% (95% CI: 96.2% - 99.8%)
  % Agreement: 96.5% (95% CI: 94.5% - 98.5%) |
  | Precision | Coefficient of Variation (CV) 0.989 between sites.
  97.1% (133/137) agreement between three sites (excluding equivocals). |

2. Sample Size Used for the Test Set and Data Provenance

• Comparative Agreement Study (Table 1):
  • Test Set Sample Size: 355 sera (86 positive by IFA, 16 equivocal by IFA, 253 negative by IFA).
  • Data Provenance: Retrospective. Sera were from "normal individuals of various ages, gender, and geographical areas." The studies were conducted at R&D laboratories of commercial companies located in Maryland and New York, affiliated with the manufacturer.
• Precision Studies (Tables 2, 3, 4):
  • Test Set Sample Size: 7 sera, each assayed 10 times in 3 different assays at 2 different sites (total 60 tests per sera for inter-site precision, 30 tests per sera for inter-assay precision within each site).
  • Data Provenance: Retrospective (sera likely selected for different activity levels), performed at 2 sites affiliated with the manufacturer.
• Paired Serum Analysis:
  • Test Set Sample Size: 9 serum pairs.
  • Data Provenance: Retrospective, serum pairs showing changes in Complement Fixation (CF) titer.
• Reproducibility Study:
  • Test Set Sample Size: 50 different sera.
  • Data Provenance: Retrospective, conducted at three different sites: two R&D laboratories at commercial companies (Maryland and New York, affiliated with the manufacturer) and one large clinical laboratory (Pennsylvania).

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts

There is no mention of "experts" in the context of establishing ground truth in the traditional sense (e.g., medical professionals reviewing cases).

• For the Comparative Agreement Study: The "ground truth" for comparison was the results of a commercial IFA kit. The document states, "Please be advised that "% agreement positive" and "% agreement negative" refer to the comparison of this assay's results to that of a similar assay. There was not an attempt to correlate the assay's results with disease presence or absence. No judgment can be made on the comparison assay's accuracy to predict disease." This clarifies that the IFA kit was the reference standard, not a true clinical ground truth established by experts.

4. Adjudication Method for the Test Set

Not applicable. The ground truth was established by a single predicate device (commercial IFA kit) or by the device itself for precision and reproducibility. There was no human adjudication process described. Equivocal results from the predicate IFA were excluded from agreement calculations, but this is not an adjudication process.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs without AI Assistance

Not applicable. This device is an in-vitro diagnostic ELISA kit, not an AI-assisted diagnostic tool that requires human readers for interpretation in the manner typically associated with MRMC studies in medical imaging. The comparison is between two laboratory assays.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) Was Done

This is an inherently standalone device as it is an ELISA kit. Its performance is measured directly through its reaction with serum samples, producing a measurable color intensity that is read photometrically. The results are quantitative and then interpreted qualitatively (positive/negative/equivocal) based on pre-defined cut-offs. There is no "human-in-the-loop" once the assay is performed and read by the instrument, beyond potentially interpreting the final qualitative result.

7. The Type of Ground Truth Used

• For Comparative Agreement, Paired Serum Analysis: The ground truth was the results of a predicate commercial IFA kit (for agreement) or a Complement Fixation (CF) titer (for seroconversion) for Chlamydia. It is explicitly stated that there was no attempt to correlate the assay's results with disease presence or absence, and therefore, no true clinical or pathological ground truth was established in these comparative studies.
• For Precision and Reproducibility: "Expected results" for reproducibility were derived from "previous Trinity Biotech ELISA testing of the samples." For precision, the study aimed to evaluate the consistency of the device's own measurements.

8. The Sample Size for the Training Set

Not applicable. This is a traditional in-vitro diagnostic kit, not a machine learning model. There is no concept of a "training set" in the context of developing this device. The development process would involve iterative optimization of assay components and protocols, rather than training an algorithm on a dataset.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for this type of device.

Ask a specific question about this device

The Trinity Biotech Captia™ Borrelia burgdorferi IgG/IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative presumptive detection of total (IgG/IgM) antibodies to Borrelia burgdorferi in human serum. This ELISA should only be used for patients with signs and symptoms that are consistent with Lyme disease. Equivocal or positive results must be supplemented by testing with a standardized Western blot procedure. Positive supplemental results are supportive evidence of exposure to B. burgdorferi and can be used to support a clinical diagnosis of Lyme disease.

The Borrelia burgdorferi IgG/IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative presumptive detection of total (IgG/IgM) antibodies to Borrelia burgdorferi in human serum. This ELISA should only be used for patients with signs and patients with symptoms that are consistent with Lyme disease. Equivocal or positive results should be supplemented by testing with a standardized Western blot procedure. Positive supplemental results are supportive evidence of exposure to B. burgdorferi and can be used to support a clinical diagnosis of Lyme disease.

The Borrelia burgdorferi IgG/IgM ELISA test is an enzyme linked immunosorbent assav to detect IgG/IgM antibodies to Borrelia burgdorferi. Purified Borrelia burgdorferi antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG/IgM is added to each well. If antibody is present, it will bind to the antibody attached to the antigen on the well. After incubation the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present. the substrate will undergo a color change. After an incubation period the reaction is stopped and the color intensity is measured photometrically, producing and indirect measurement of specific antibody in the patient specimen.

Here's an analysis of the acceptance criteria and the study that proves the device meets them, based on the provided text:

Device: Borrelia burgdorferi IgG/IgM ELISA Test Kit (Trinity Biotech Captia™ Borrelia burgdorferi IgG/IgM ELISA)

Indications for Use: Qualitative presumptive detection of total (IgG/IgM) antibodies to Borrelia burgdorferi in human serum, for patients with signs and symptoms consistent with Lyme disease. Equivocal or positive results must be supplemented by testing with a standardized Western blot procedure.

1. Table of Acceptance Criteria and Reported Device Performance

The provided document doesn't explicitly state numerical acceptance criteria in the typical sense for assay performance (e.g., "sensitivity must be >90%"). Instead, it demonstrates performance through comparative studies and precision testing. The acceptance criteria appear to be implicitly defined by demonstrating equivalence to a predicate device (BioWhittaker's Lyme STAT test) and acceptable precision, as well as testing against a characterized CDC panel and assessing cross-reactivity.

Here's a table summarizing the performance metrics and results provided:

• Specific agreement by time after onset:
  • Normals: 100% (5/5)
  • 1 year: 100.0% (8/8) |
    | Equivalence to Predicate Device (Study 2) | Demonstrate similar performance to the predicate device (BioWhittaker Lyme STAT) in terms of 1-step positivity/equivocality rates and 2-step positive rates. | 1-step (ELISA) Pos. or Eq.:
• Trinity: 9.1% (4.8% - 13.4%) (16/176)
• Lyme Stat: 7.4% (3.4% - 11.3%) (13/176)
  1-step Pos. or Eq. & 2-step (WB) Pos.:
• Trinity: 4% (1.0% - 6.9%) (7/176)
• Lyme Stat: 2.8% (0.3% - 5.3%) (5/176)
  2-step Pos. among 1-step Pos. or Eq.:
• Trinity: 44% (18.9% - 68.6%) (7/16)
• Lyme Stat: 39% (11.5% - ) (5/13) |
  | Precision (Inter-Assay) | Achieve precision with a Coefficient of Variation (CV)

Ask a specific question about this device

The Trinity Biotech Captia ENA Profile Enzyme-Linked Immunosorbent Assays (ELISA) is intended for the detection of antibodies to individually coated Smith, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and Jo-1 in a single serum specimen. The results of the assay are to be used as an aid in the diagnosis of Systemic Lupus Erythematosis (SLE), scleroderma, Sjogren's syndrome (SS), or other systemic rheumatic diseases.

Not Found

This document is a 510(k) clearance letter from the FDA for a diagnostic device, not a study report. As such, it does not contain the detailed information required to describe acceptance criteria and a study proving device performance in the way a scientific publication or a full regulatory submission would.

Therefore, I cannot extract the requested information. The document focuses on regulatory approval, stating that the device is "substantially equivalent" to a legally marketed predicate device, rather than providing a detailed breakdown of a clinical study demonstrating its performance against specific acceptance criteria.

Ask a specific question about this device